Summit Therapeutics Inc (NAS:SMMT)

Q2 2026 Summit Therapeutics Inc Earnings Call Transcript

Jul 23, 2026 / 08:30 PM GMT

Release Date Price: $14.98 (+1.63%)

Transcript 10-Q8-K

Key Points

Positve

Summit Therapeutics Inc (SMMT) reported a strong cash position of approximately $690.7 million at the end of Q2 2026, an increase from the previous quarter.
Ivanizumab, the company's lead investigational asset, has shown positive data in four Phase III clinical studies, leading to two approvals in China and a pending BLA with the U.S. FDA.
The HARMONY trial demonstrated a consistent overall survival benefit across different geographic regions, indicating the potential for global applicability.
Summit Therapeutics Inc (SMMT) has established collaborations with major pharmaceutical companies like GSK and Arcus Biosciences to explore novel combinations with Ivanizumab.
The company has initiated over 50 clinical trials for Ivanizumab, covering a wide range of solid tumors, indicating a robust and diverse pipeline.

Negative

The company reported an increase in GAAP operating expenses to $220.5 million in Q2 2026, primarily due to higher R&D expenses.
Despite positive trial results, Ivanizumab has not yet achieved statistically significant overall survival benefits in some settings, which is necessary for FDA approval.
The enrollment for some trials, such as HARMONY 3, was back-end loaded, potentially affecting the follow-up time and interim analysis results.
There is a risk of competition from other emerging therapies like amivantamab and Trope 2 ADCs, which could impact Ivanizumab's market positioning.
The company has no debt, but it relies heavily on ATM facilities for financing, which could pose risks if market conditions change.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

SMMT.OQ - Summit Therapeutics Inc
Q2 2026 Summit Therapeutics Inc Earnings Call
Jul 23, 2026 / 08:30PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Good afternoon, and welcome to Summit Therapeutics Q2 2026 Earnings Call. All participants will be in listen-only mode until the question-and-answer portion of this call.

We do not expect any technical difficulties today. However, in the event that we lose the webcast connection and are unable to provide any updates, please wait up to 10 minutes for resolution.

Please refer to the company's website for updates. Please note that today's call is being recorded.

After today's prepared remarks, we will host a question-and-answer session. If you would like to ask a question, please press star one to raise your hand. To withdraw your question, press star one again.

At this time, I would like to

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.